Salix Pharmaceuticals (SLXP) Price Target Reduced to $102 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Salix Pharmaceuticals (SLXP) Price Target Lowered to $102 at Deutsche Bank (Earlier)
November 10, 2014 3:45 PM ESTDeutsche Bank earlier maintained a Hold rating on Salix Pharmaceuticals (NASDAQ: SLXP) and reduced its price target to $102.00 (from $134.00). Last week the stock declined after issuing weak Q4 outlook.
Analyst Gregg Gilbert said, "While our PT suggests decent upside from the current... More
Salix Pharmaceuticals (SLXP) Target Sliced to $119 at Piper Jaffray on Inventory Disaster
November 7, 2014 9:18 AM ESTPiper Jaffray analyst David Amsellem cut estimates and his price target on Salix Pharmaceuticals (NASDAQ: SLXP) to $119.00 (from $189.00) while maintaining an Overweight rating.
Amsellem commented, "It is now clear that Salixs management (or rather mismanagement) of inventory has been an unmitigated disaster that will depress... More
William Blair Downgrades Salix Pharmaceuticals (SLXP) to Market Perform
November 7, 2014 7:16 AM ESTWilliam Blair downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreStifel Downgrades Salix Pharmaceuticals (SLXP) to Hold
November 7, 2014 7:15 AM ESTStifel downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreMizuho Securities Downgrades Salix Pharmaceuticals (SLXP) to Neutral
November 7, 2014 7:15 AM ESTMizuho Securities downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreSalix Pharma (SLXP) Misses Q3 EPS by 3c; Issues Weak Q4 Outlook
November 6, 2014 4:26 PM ESTSalix Pharma (NASDAQ: SLXP) reported Q3 EPS of $1.53, $0.03 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $354.7 million versus the consensus estimate of $394 million.
Salix Pharma sees FY2014 EPS of $5.20, versus the consensus of $6.17. Salix Pharma sees FY2014 revenue of... More
Salix Pharma (SLXP) CFO Derbyshire Resigns
November 6, 2014 4:06 PM ESTSalix Pharma (NASDAQ: SLXP) announced the appointment of Timothy J. Creech as Acting Chief Financial Officer of the Company, effective immediately. He succeeds Adam C. Derbyshire, who resigned his position at the Company.
Mr. Creech, who joined the Company in 2007, has most recently been serving as the Companys Senior Vice President, Finance and... More
